Immunology of chronic beryllium disease

Current Opinion in Allergy and Clinical Immunology

Volumn 8, Issue 2, 2008, Pages 126-134

  Samuel, George ^a   Maier, Lisa A ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Berylliosis; CBD; HLA DPB1*Glu69; HLA DRB1*13; Polymorphisms; T cells

Indexed keywords

AMINO ACID; GLUTAMIC ACID; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA1;

ALLELE; BERYLLIOSIS; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; DIAGNOSTIC PROCEDURE; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRANULOMATOUS INFLAMMATION; HEREDITY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; SENSITIZATION; T LYMPHOCYTE; TH1 CELL; TREATMENT DURATION;

BERYLLIOSIS; CHRONIC DISEASE; CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; GRANULOMA; HLA-D ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; OCCUPATIONAL EXPOSURE; POLYMORPHISM, GENETIC; TH1 CELLS;

EID: 43249130919     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282f824a4     Document Type: Review

References (95)

1. Balkissoon RC, Newman LS. Beryllium copper alloy (2%) causes chronic beryllium disease. J Occup Environ Med 1999; 41:304-308.
2. Maier L, Gunn C, Newman L. Beryllium disease. In: Rom W, editor. Envionmental and occupational medicine. Philadelphia: Lippincott-Raven Publishers; 2006. pp. 1021-2038.
3. Henneberger PK, Goe SK, Miller WE, et al. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J Occup Environ Hyg 2004; 1:648-659.
4. Infante PF, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet 2004; 363:415-416.
5. Kreiss K, Mroz MM, Zhen B, et al. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis 1993; 148:985-991.
6. Kreiss K, Mroz MM, Newman LS, et al. Machining risk of beryllium disease and sensitization with median exposures below 2mg/m3. Am J Industr Med 1996; 30:16-25.
7. Kelleher PC, Martyny JW, Mroz MM, et al. Beryllium particulate exposure and disease relations in a beryllium machining plant. J Occup Environ Med 2001; 43:238-249.
8. Kreiss K, Wasserman S, Mroz MM, Newman LS. Beryllium disease screening in the ceramics industry. Blood lymphocyte test performance and exposure-disease relations. J Occup Med 1993; 35:267-274.
9. Welch L, Ringen K, Bingham E, et al. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites. Am J Ind Med 2004; 46:207-218.
10. Sackett HM, Maier LA, Silveira LJ, et al. Beryllium medical surveillance at a former nuclear weapons facility during cleanup operations. J Occup Environ Med 2004; 46:953-961.
11. Newman LS, Lloyd J, Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect 1996; 104:937-943.
12. Newman LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect 1996; 104:953-956.
13. Newman LS. Immunology, genetics, and epidemiology of beryllium disease. Chest 1996; 109:40S-43S.
14. Rossman MD, Kern JA, Elias JA, et al. Proliferative response of bronchoalveolar lymphocytes to beryllium: A test for chronic beryllium disease. Ann Intern Med 1988; 108:687-693.
15. Kreiss K, Newman LS, Mroz MM, Campbell PA. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989; 31:603-608.
16. Mroz MM, Kreiss K, Lezotte DC, et al. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 1991; 88:54-60.
17. Saltini C, Winestock K, Kirby M, et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med 1989; 320:1103-1109.
18. Maier LA, McGrath DS, Sato H, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol 2003; 171:6910-6918.
19. McCanlies EC, Kreiss K, Andrew M, Weston A. HLA-DPB1 and chronic beryllium disease: a HuGE review. Am J Epidemiol 2003; 157:388-398.
20. Rossman MD, Stubbs J, Lee CW, et al. Human leukocyte antigen Class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002; 165:788-794.
21. Wang Z, White P, Petrovic M, et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol 1999; 163:1647-1653.
22. Wang Z, Farris GM, Newman LS, et al. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 2001; 165:27-38.
23. Kalra R, Singh SP, Savage SM, et al. Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores. J Pharmacol Exp Ther 2000; 293:166-171.
24. Fontenot AP, Palmer BE, Sullivan AK, et al. Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J Clin Invest 2005; 115:2886-2893.
25. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005; 171:54-60.
26. Pott GB, Palmer BE, Sullivan AK, et al. Frequency of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J Allergy Clin Immunol 2005; 115:1036-1042.
27. Maier LA, Kittle LA, Mroz MM, Newman LS. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. Am J Ind Med 2003; 43:592-601.
28. Kriebel D, Brain JD, Sprince NL, Kazemi H. The pulmonary toxicity of beryllium. Am Rev Respir Dis 1988; 137:464-473.
29. Newman LS, Kreiss K, King TE Jr, et al. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989; 139:1479-1486.
30. Sawyer RT, Abraham JL, Daniloff E, Newman LS. Secondary ion mass spectroscopy demonstrates retention of beryllium in chronic beryllium disease granulomas. J Occup Environ Med 2005; 47:1218-1226.
31. Freiman DG, Hardy HL. Beryllium disease: The relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. Beryllium Case Registry. Hum Pathol 1970; 1:25-44.
32. Tepper LB, Hardy HL, Chamberlin RI. Toxicity of beryllium compounds. In: Browning E, editor. Elsevier monographs on toxic agents. Amsterdam: Elsevier Publishing Company; 1961. pp. 1-190.
33. Hardy HL. Beryllium poisoning: Lessons in control of man-made disease. N Engl J Med 1965; 273:1188-1199.
34. Finkel AJ, Hamilton A, Hardy HL. Beryllium. In: Finkel AJ, editor. Hamilton and Hardy's industrial toxicology. 4th ed. Boston: John Wright; 1983 pp. 26-36.
35. International Labor Organization. Guidelines for the Use of ILO International Classification of Radiographs of Pneumoconioses. Geneva: International Labour Office; 1980.
36. Aronchick JM, Rossman MD, Miller WT. Chronic beryllium disease: Diagnosis, radiographic findings, and correlation with pulmonary function tests. Radiology 1987; 163:677-682.
37. Wilson SA. Delayed chemical pneumonitis or diffuse granulomatosis of the lung due to beryllium. Radiology 1948; 50:770-779.
38. Robert AG. A consideration of the roentgen diagnosis of chronic pulmonary granulomatosis of beryllium workers. AJR 1950; 63:467-487.
39. Weber AL, Stoeckle JD, Hardy HL. Roentgenologic patterns in long-standing beryllium disease: Report of eight cases. AJR 1965; 93:879-890.
40. Newman LS, Buschman DL, Newell JD Jr, Lynch DA. Beryllium disease: Assessment with CT. Radiology 1994; 190:835-840.
41. Harris KM, McConnochie K, Adams H. The computed tomographic appearances in chronic berylliosis. Clin Radiol 1993; 47:26-31.
42. Akira M. High-resolution CT in the evaluation of occupational and environmental disease. Radiol Clin North Am 2002; 40:43-59.
43. Naccache JM, Marchand-Adam S, Kambouchner M, et al. Ground-glass computed tomography pattern in chronic beryllium disease: pathologic substratum and evolution. J Comput Assist Tomogr 2003; 27:496-500.
44. Andrews JL, Kazemi H, Hardy H. Patterns of lung dysfunction in chronic beryllium disease. Am Rev Respir Dis 1969; 100:791-800.
45. Pappas GP, Newman LS. Early pulmonary physiologic abnormalities in beryllium disease. Am Rev Respir Dis 1993; 148:661-666.
46. Stoeckle JD, Hardy HL, Weber AL. Chronic beryllium disease: Long-term follow-up of sixty cases and selective review of the literature. Am J Med 1969; 46:545-561.
47. Lundgren RA, Maier LA, Rose CS, et al. Indirect and direct gas exchange at maximum exercise in beryllium sensitization and disease. Chest 2001; 120:1702-1708.
48. Saltini C, Richeldi L, Losi M, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J 2001; 18:677-684.
49. Fontenot AP, Torres M, Marshall WH, et al. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease. Proc Natl Acad Sci USA 2000; 97:12717-12722.
50. Scott BL, Wang Z, Marrone BL, Sauer NN. Potential binding modes of beryllium with the class II major histocompatibility complex HLA-DP: a combined theoretical and structural database study. J Inorg Biochem 2003; 94:5-13.
51. Snyder J, Demchuk E, McCanlies E, et al. Impact of negatively charged patches of the surface of ARHC class II antigen-presenting proteins on risk of chronic beryllium disease. Journal of Royal Society Interface 2007; 10:1098. Glu 69 alleloforms of MHC class II antigen presenting proteins with the greatest negative charge convey equal risk of beryllium sensitization, but increased risk of chronic beryllium disease, as well as progression from sensitization to disease.
52. Fontenot AP, Keizer TS, McCleskey M, et al. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells. J Immunol 2006; 177:3874-3883.
53. Amicosante M, Fontenot AP. T cell recognition in chronic beryllium disease. Clin Immunol 2006; 121:134-143.
54. Fontenot A, Falta M, Newman L, Kotzin B. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol 1999; 163:1026-1029.
55. Fontenot AP, Kotzin BL, Comment CL, Newman LS. Expansions of T cell subsets expressing particular T cell receptor variable regions in chronic beryllium disease. Am J Respir Cell Mol Biol 1998; 18:581-589.
56. Fontenot AP, Falta MT, Freed BM, et al. Identification of pathogenic T cells in patients with beryllium-induced lung disease. J Immunol 1999; 163:1019-1026.
57. Lombardi G, Germain C, Uren J, et al. HLA-DP allele-specific T cell responses to beryllium account for DP-associated susceptibility to chronic beryllium disease. J Immunol 2001; 166:3549-3555.
58. Fontenot AP, Newman LS, Kotzin BL. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP. Clin Immunol 2001; 100:4-14.
59. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262:242-244.
60. Richeldi L, Kreiss K, Mroz MM, et al. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med 1997; 32:337-340.
61. McCanlies EC, Ensey JS, Schuler CR, et al. The association between HLA-DPB1Glu69 and chronic beryllium disease and beryllium sensitization. Am J Ind Med 2004; 46:95-103.
62. Amicosante M, Berretta F, Rossman M, et al. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir Res 2005; 6:94.
63. Weston A, Snyder J, McCanlies EC, et al. Immunogenetic factors in beryllium sensitization and chronic beryllium disease. Mutat Res 2005; 592:68-78.
64. Castelli FA, Buhot C, Sanson A, et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol 2002; 169:6928-6934.
65. Diaz G, Amicosante M, Jaraquemada D, et al. Functional analysis of HLA-DP polymorphism: a crucial role for DPbeta residues 9, 11, 35, 55, 56, 69 and 84-87 in T cell allorecognition and peptide binding. Int Immunol 2003; 15:565-576.
66. Berretta F, Butler RH, Diaz G, et al. Detailed analysis of the effects of Glu/Lys beta69 human leukocyte antigen-DP polymorphism on peptide-binding specificity. Tissue Antigens 2003; 62:459-471.
67. Fontenot AP, Kotzin BL. Chronic beryllium disease: immune-mediated destruction with implications for organ-specific autoimmunity. Tissue Antigens 2003; 62:449-458.
68. Fontenot AP, Maier LA. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. Trends Immunol 2005; 26:543-549.
69. Bill JR, Mack DG, Falta MT, et al. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II β-Chain. J Immunol 2005; 175:7029-7037.
70. Fontenot AP, Canavera SJ, Gharavi L, et al. Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. J Clin Invest 2002; 110:1473-1482.
71. Amicosante M, Berretta F, Franchi A, et al. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells. Eur Respir J 2002; 20:1174-1178.
72. Sawyer RT, Parsons CE, Fontenot AP, et al. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol 2004; 31:122-130.
73. Saltini C, Kirby M, Trapnell BC, et al. Biased accumulation of T lymphocytes with "memory"-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. J Exp Med 1990; 171:1123-1140.
74. Fontenot AP, Maier LA, Canavera SJ, et al. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J Immunol 2002; 168:3627-3634.
75. Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis: State of art. Am Rev Respir Dis 1987; 135:747-760.
76. Hardy HL, Tabershaw IR. Delayed chemical pneumonitis in workers exposed to beryllium compounds. J Industr Hyg Toxicol 1946; 28:197-211.
77. Bost TW, Riches DWH, Schumacher B, et al. Alveolar macrophages from patients with beryllium disease and sarcoidosis express mRNA for TNF-α and IL-6 but not IL-1β. Am J Respir Cell Mol Biol 1994; 10:506-513.
78. Tinkle SS, Kittle LA, Schumacher BA, Newman LS. Beryllium induces IL-2 and IFN-gamma in berylliosis. J Immunol 1997; 158:518-526.
79. Saltini C, Amicosante A, Franchi A, et al. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model. Eur Respir J 1998; 12:1463-1475.
80. Zhang MT, Kevin J. Tumor Necrosis Factor. In: Thomson AW, editor. The cytokine handbook. San Diego: Academic Press; 1998. pp. 517-548.
81. Maier LA, Sawyer RT, Bauer RA, et al. High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med 2001; 164:1192-1199.
82. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2:116-126.
83. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995; 2:555-559.
84. Harding FA, McArthur JG, Gross JA, et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356:607-609.
85. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248:1349-1356.
86. Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994; 152:2675-2685.
87. Fontenot AP, Gharavi L, Bennett SR, et al. CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells. J Clin Invest 2003; 112:776-784.
88. Tinkle SS, Kittle LA, Newman LS. Partial IL-10 inhibition of the cell-mediated immune response in chronic beryllium disease. J Immunol 1999; 163:2747-2753.
89. Jonth AC, Silveira L, Fingerlin TE, et al. TGF-beta1 variants in chronic beryllium disease and sarcoidosis. J Immunol 2007; 179:4255-4262. This case control study examined differences in TGF-β variants between sarcoidosis and CBD and respectively matched controls. The -509C and codon 10T variants, associated with lower levels of TGF- β, were associated with markers of disease severity in both diseases, while -509T and codon 10C were protective against severe disease in both CBD and sarcoidosis.
90. Dotti C, D'Apice MR, Rogliani P, et al. Analysis of TNF-alpha promoter polymorphisms in the susceptibility to beryllium hypersensitivity. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:29-34.
91. Gaede KI, Amicosante M, Schurmann M, et al. Function associated transforming growth factor-beta gene polymorphism in chronic beryllium disease. J Mol Med 2005; 83:397-405.
92. McCanlies EC, Schuler CR, Kreiss K, et al. TNF-alpha polymorphisms in chronic beryllium disease and beryllium sensitization. J Occup Environ Med 2007; 49:446-452. Genotyping was performed in a population-based cohort of 886 beryllium-exposed workers (64 sensitized, 92 with chronic beryllium disease) in order to examine associations with -308 and -238 TNF promoter polymorphisms. No significant associations with beryllium sensitization nor disease were observed.
93. Sato H, Silviera L, Fingerlin T, et al. TNF polymorphism and bronchoalveolar lavage cell TNF-a levels in chronic beryllium disease and beryllium sensitization. J Allergy Clin Immunol 2007; 119:687-696. Five TNF promoter polymorphisms were genotyped among 147 subjects with chronic beryllium disease, 112 sensitized subjects and 323 controls. No significant associations were observed between any TNF polymorphism nor haplotype and subject group.
94. Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol 2006; 176:7354-7360.
95. Sato H, Spagnolo P, Silveira L, et al. BTNL2 allele associations with chronic beryllium disease in HLA-DPB1 *Glu69-negative individuals. Tissue Antigens 2007; 70:480-486. This study illustrated the potential association of a specific butyrophilin-like 2 (BTNL2) polymorphism with a subset of CBD subjects who are HLA-DPB1 *Glu69 negative.